Format

Send to:

Choose Destination
See comment in PubMed Commons below
Blood. 2012 Oct 4;120(14):2776-7. doi: 10.1182/blood-2012-08-446534.

Carfilzomib in multiple myeloma: gold, silver, or bronze?

Author information

  • 1Princess Margaret Hospital, Canada.

Abstract

In this issue of Blood, Siegel and colleagues report that the next-generation proteasome inhibitor carfilzomib, when administered as a single agent, can produce meaningful disease control in heavily pretreated patients with relapsed/refractory multiple myeloma.(1)

PMID:
23043023
[PubMed - indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk